JPH02121920A - Solution of sodium cromoglicate for external use - Google Patents
Solution of sodium cromoglicate for external useInfo
- Publication number
- JPH02121920A JPH02121920A JP63277092A JP27709288A JPH02121920A JP H02121920 A JPH02121920 A JP H02121920A JP 63277092 A JP63277092 A JP 63277092A JP 27709288 A JP27709288 A JP 27709288A JP H02121920 A JPH02121920 A JP H02121920A
- Authority
- JP
- Japan
- Prior art keywords
- benzalkonium chloride
- chlorobutanol
- sodium
- sodium cromoglicate
- acid ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 title abstract description 14
- 229960000265 cromoglicic acid Drugs 0.000 title abstract description 12
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 29
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 229960004926 chlorobutanol Drugs 0.000 claims abstract description 22
- 239000002253 acid Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000003889 eye drop Substances 0.000 abstract description 8
- 238000002156 mixing Methods 0.000 abstract description 7
- 239000000243 solution Substances 0.000 abstract description 7
- 230000002421 anti-septic effect Effects 0.000 abstract description 5
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 239000007923 nasal drop Substances 0.000 abstract description 3
- 239000006172 buffering agent Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000006196 drop Substances 0.000 abstract description 2
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 abstract 2
- -1 p- hydroxybenzoic acid ester Chemical class 0.000 abstract 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 description 17
- 239000003755 preservative agent Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229940012356 eye drops Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 229960002684 aminocaproic acid Drugs 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229960001716 benzalkonium Drugs 0.000 description 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 229940109248 cromoglycate Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 241000078604 Diplophyllum albicans Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- LSTJLLHJASXKIV-UHFFFAOYSA-N amino hexanoate Chemical compound CCCCCC(=O)ON LSTJLLHJASXKIV-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- GKWDNNXFOHIETQ-UHFFFAOYSA-M sodium;1-chlorobutan-1-ol;chloride Chemical compound [Na+].[Cl-].CCCC(O)Cl GKWDNNXFOHIETQ-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
「産業上の利用分野」
本発明は塩化ベンザルコニウムとクロロブタノールを配
合するかまたはさらにパラオキシ安息香酸エステルを加
えることによシ防腐効果を高め、刺激性の少ないクロモ
グリク酸ナトリウムの外用液剤に関する。Detailed Description of the Invention "Field of Industrial Application" The present invention improves the preservative effect by blending benzalkonium chloride and chlorobutanol or by further adding paraoxybenzoic acid ester, thereby producing a less irritating chromoglycan. This invention relates to a liquid preparation for external use of sodium acid.
「従来技術、発明が解決しようとする課題および課題を
解決するだめの手段」
クロモグリク酸ナトリウムは点眼液や吸入液の形態でア
レルギー性疾患の治療剤として用いられている。ところ
が、クロモグリク酸ナトリウムを点眼液や吸入液などの
外用液剤とする時、通常外用液剤で使用されている濃度
で防腐剤を配合してもその効果が不充分なため、種々の
方法を検討しなければならなかつ九。その一つとして、
市販されている外用液剤では塩化ベンザルコニウムにエ
デト酸す） ＩＪウムを配合する方法が用いられている
。"Prior Art, Problems to be Solved by the Invention, and Means for Solving the Problems" Sodium cromoglycate is used as a therapeutic agent for allergic diseases in the form of eye drops and inhalation solutions. However, when making sodium cromoglycate into external liquid preparations such as eye drops and inhalation solutions, the effect is insufficient even if preservatives are added at the concentrations normally used in external liquid preparations, so various methods have been considered. Must be nine. As one of them,
In commercially available liquid preparations for external use, a method is used in which benzalkonium chloride is mixed with IJium edetate.
本発明者等社塩化ベンザルコニウムに他の防腐剤を配合
するという観点より研究を進め、より低員度でも充分に
防腐効果が発揮できかつ刺激性の少ないクロモグリク酸
ナトリウムの外用液剤を得ることに成功した。The present inventors have conducted research from the viewpoint of blending other preservatives with benzalkonium chloride, and obtained a topical solution of sodium cromoglycate that is sufficiently effective as a preservative even at a lower concentration and is less irritating. succeeded in.
「発明の開示」
本発明は塩化ベンザルコニウムとクロロブタノールを配
合するかまたはさらにパラオキシ安息香酸エステルを加
えることＫより防腐効果を高め、刺激性の少ないクロモ
グリク酸ナトリウムの外用液剤に関する。``Disclosure of the Invention'' The present invention relates to a topical liquid preparation of sodium cromoglycolate which has a higher antiseptic effect and is less irritating by blending benzalkonium chloride and chlorobutanol or further adding paraoxybenzoic acid ester.
本発明でいう外用液剤としては点眼液、点鼻液、吸入液
などが挙げられる。又、パラオキシ安息香酸エステルと
はバラオキシ安息香酸のエチル、ブチル等の炭素数１〜
６の低級アルキル基のエステルをいう。Examples of external liquid preparations in the present invention include eye drops, nasal drops, and inhalation liquids. In addition, paraoxybenzoic acid ester refers to paraoxybenzoic acid having 1 to 1 carbon atoms such as ethyl or butyl.
Refers to the ester of the lower alkyl group of No. 6.
本発明におけるクロモグリク酸ナトリウムの配合量は治
療効果の発揮できる濃度であればよく、好ましくは１〜
４％である。The amount of sodium cromoglycate to be blended in the present invention may be any concentration that can exhibit therapeutic effects, and is preferably 1 to 1.
It is 4%.
クロモグリク酸す） ＩＪウムは点眼液や吸入液の形態
でアレルギー性疾患の治療剤として用いられている。と
ころが、クロモグリク酸ナトリウムを点眼液や吸入液な
どの外用液剤とする時、その薬物の特性として通常外用
液剤で汎用されている防腐剤である塩化ベンザルコニウ
ムを通常の濃度（０，００５％）で用いてもその効果は
充分ではなかった。市販されている外用液剤では０．０
１％の濃度の塩化ベンザルコニウムを用い、さらにエデ
ト酸ナトリウムを配合して効果を高めている。Cromolytic acid) IJum is used as a therapeutic agent for allergic diseases in the form of eye drops and inhalation solutions. However, when making sodium cromoglycate into external liquid preparations such as eye drops and inhalation liquids, the characteristics of the drug include benzalkonium chloride, a preservative commonly used in external liquid preparations, at the usual concentration (0,005%). Even when used, the effect was not sufficient. 0.0 for commercially available external liquids
Benzalkonium chloride at a concentration of 1% is used, and sodium edetate is added to enhance the effect.
本発明者等は塩化ベンザルコニウムに他の防腐剤を配合
するという観点よシ研究を進めた。まず、塩化ベンザル
コニウムとパラオキシ安息香酸エステルを併用すること
が考えられるが、両者を併用する場合、塩化ベンザルコ
ニウムの量がｏ、ｏ ｏ ｓチを越えると白濁が生じ、
ｏ、ｏｏｓｓ以下の配合では白濁は生じないものの、そ
の防腐効果は溝足できるものではなかった。（防腐効果
試験の項参照）
このように、外用液剤で汎用される防腐剤を′通常の濃
度で使用しても、又、単純に２ｆｌＪｌ類の防腐剤を組
み合わせても充分な防腐効果は得られなかった。The present inventors have conducted research from the viewpoint of adding other preservatives to benzalkonium chloride. First, it is possible to use benzalkonium chloride and paraoxybenzoic acid ester together, but when using both together, if the amount of benzalkonium chloride exceeds o, o o s, cloudiness will occur,
Although white turbidity did not occur when the formulation was less than o.ooss, the preservative effect was not satisfactory. (Refer to the section on preservative effect testing.) In this way, sufficient preservative effects cannot be obtained even if preservatives commonly used in external liquids are used at normal concentrations, or simply in combination with 2flJl type preservatives. I couldn't.
そこで、本発明者等はクロモグリク酸ナトリウムの外用
液剤の防腐剤の組み合わせについてさらに鋭意検討を行
なったところ、塩化ペンザルコニクムとクロロブタノー
ルを併用することにより充分な防腐効果が得られること
を見い出した。詳細なデータについては防腐効果試験の
項で述べるが、塩化ベンザルコニウム単独では０．０１
％と外用液剤に用いるものとしては比較的高い濃度で配
合しても、２週間後での測定結果でＰａｓｕｄｏｍｏｎ
ｕｓａｅｒｕｇｉｎｏａａ が完全に死滅しておらず、
その防腐効果は不充分であった。これに対して、塩化ペ
ンザルコ二りムとクロロブタノールを併用したものでは
いずれも２週間後では菌が完全に死滅しており、明らか
に防腐効果の増大が認められた。さらに、３種類目の防
腐剤としてパラオキシ安息香酸エステルを用いることに
よシ、クロロブタノールの配合量を減少させることも可
能であることを見い出した。Therefore, the present inventors conducted further intensive studies on the combination of preservatives for external liquid preparations of sodium cromoglycate, and discovered that a sufficient preservative effect could be obtained by using pensarconicum chloride and chlorobutanol in combination. Detailed data will be described in the section on preservative effect testing, but benzalkonium chloride alone has a
%, even if it is formulated at a relatively high concentration for use in external liquid preparations, the measurement results after 2 weeks show that Pasudmon
usaeruginoaa has not completely died out,
Its antiseptic effect was insufficient. On the other hand, in both cases where penzarkonium chloride and chlorobutanol were used in combination, the bacteria were completely killed after two weeks, clearly showing an increase in the preservative effect. Furthermore, it has been found that by using paraoxybenzoic acid ester as the third type of preservative, it is also possible to reduce the amount of chlorobutanol blended.
塩化ベンザルコニウムは非常に優れた防腐剤であるが、
高濃度で用いると刺激が生じたシ、角膜等に障害が生じ
る可能性がある。従って、防腐剤として塩化ベンザルコ
ニウムを用いる場合、できるだけ低濃度に抑える必要が
あった。本発明者等は防腐効果の発揮しにくいクロモグ
リク酸ナトリウムの外用液剤において、塩化ベンザルコ
ニウムの濃度を他の防腐剤を配合することによって低く
抑えることに成功した。その結果、刺激性の少ない有用
なりロモグリク酸ナトリウムの外用液剤が得られること
を見い出した。Benzalkonium chloride is an excellent preservative, but
If used in high concentrations, irritation may occur and damage may occur to the cornea, etc. Therefore, when using benzalkonium chloride as a preservative, it was necessary to keep the concentration as low as possible. The present inventors have succeeded in suppressing the concentration of benzalkonium chloride in a topical liquid preparation of sodium cromoglycolate, which is difficult to exhibit a preservative effect, by incorporating other preservatives. As a result, it has been found that a useful external liquid preparation of sodium romoglycate with less irritation can be obtained.
本発明で防腐剤として用いられる塩化ベンザルコニウム
の配合量は０．０１’％以下でおればよく、好ましくは
ｏ、ｏ ｏ ｓ％以下である。又、クロロブタノールの
配合蓋としては０．５チ以下が好ましいが、パラオキシ
安息香酸二□ステルを加える場合には、その配合量をも
つと低くすることが可能となる。この場合のパラオキシ
安息香酸エステルの濃度としては０．０２５％以下が好
ましい。The amount of benzalkonium chloride used as a preservative in the present invention may be 0.01'% or less, preferably 0.01% or less. Further, the blending amount of chlorobutanol is preferably 0.5 or less, but if paraoxybenzoic acid diester is added, the blending amount can be lowered. In this case, the concentration of paraoxybenzoic acid ester is preferably 0.025% or less.
本発明の外用液剤は、通常外用液剤で使用されている緩
衝剤、等張化剤、安定化剤、ｐＨ調整剤などを用いて調
製される。そのｐＨは外用液剤として用いられるもので
あれはよく、好ましくは４．５〜７．０である。The external solution of the present invention is prepared using buffering agents, tonicity agents, stabilizers, pH adjusters, etc. that are commonly used in external solutions. The pH may be as long as it can be used as a liquid preparation for external use, and is preferably 4.5 to 7.0.
このようにして得られた外用液剤は、点眼液であれは１
回１〜数滴、１日１〜数同点眼すればよく、点鼻用や吸
入用であれば１日１〜数回専用の噴霧器を用いて噴霧す
ればよい。If the external solution obtained in this way is an eye drop, it is
It is sufficient to apply one to several drops to the eyes once or several times a day, and for nasal or inhalation use, it may be sprayed once to several times a day using a special nebulizer.
以下に実施例としてその製剤例を示す。Examples of the formulation are shown below as examples.
「実施例」
実施例１
処方ｌ １００ｍｌ中
クロモグリク酸ナトリウム ２ｙε−アミノカプ
ロン酸 ０．４ｙ塩化ベンザルコニウム
０．００５９クロロブタノール ０．２５ｙ
希塩酸 適量
滅菌精製水 適量
製法
滅菌精製水８００ｓｄＩＣクロセグリク酸ナトリウム、
ε−アミツカグロン酸、塩化ベンザルコニウム、クロロ
ブタノールを入れて溶解した後、希塩酸を用いてｐＨを
５．５ Ｋ調整する。滅菌精製水を加えて全量を１００
０ ＴＲ１とする。"Example" Example 1 Formulation 1 Sodium cromoglycate 2yε-aminocaproic acid 0.4y Benzalkonium chloride in 100ml
0.0059 Chlorobutanol 0.25y
Dilute hydrochloric acid Appropriate amount Sterile purified water Appropriate amount Manufacturing method Sterile purified water 800sdIC Sodium croseglicate,
After adding and dissolving ε-amitsukagulonic acid, benzalkonium chloride, and chlorobutanol, the pH is adjusted to 5.5 K using dilute hydrochloric acid. Add sterile purified water to bring the total volume to 100.
0 TR1.
上記と同様の方法を用いて処方２〜５の外用液剤を得た
。External liquid preparations of formulations 2 to 5 were obtained using the same method as above.
処方２１０〇−中
クロモグリク酸ナトリウム ２ノε−７ミノカプ
ロン酸 ０．４２塩化ベンザルコニウム
０．００５ｐクロロブタノール
塩化ナトリウム
希塩酸
滅菌精製水
処方３ １００ｍ中
クロモグリク酸ナトリウム
Ｃ−アミノカプロン酸
塩化ベンザルコニウム
クロロブタノール
希塩酸
滅菌精製水
処方４ １００Ｗｄ中
クロモグリク酸ナトリウム
酢醗ナトリウム
塩化ベンザルコニウム
クロロブタノール
希塩酸
滅菌精製水
処方５ １００１Ｉ／中
クロモグリク酸ナトリウム
０．２５？
０．５ｙ
適量
適量
ｙ
０．４ｙ
ｏ、ｏ ｏ ｓ ｙ
Ｏ６３ｙ
適量
適量
ｙ
０．３ ｙ
Ｏ，００５？
６３ｙ
適量
適量
ｙ
８−アミノカプロン酸 ０．４ｙ塩化ベンザルコ
ニウム ｏ、ｏ ｏ ｓ ｙクロロブタノール
０．２ｙ希塩酸 適量
滅菌精製水 適量
実施例２
処方６１０〇−中
クロモグリク酸ナトリウム ２ｙＣ−アミノカプ
ロン酸 ０．２ｙ塩化ベンザルコニウム
０．００５ｙクロロブタノール ０．１！Ｍ
’バラオキシ安息香酸エチル ｏ、ｏｏ４ｙパラ
オキシ安息香酸ブチル ０．００２ｙ希塩酸
適量
滅菌精製水 適量
製法
滅菌精製水８００ｄにクロモグリク酸ナトリウム、Ｃ−
アミツカグロン酸、塩化ベンザルコニウム、クロロブタ
ノール、バラオキシ安息香酸エチル、パラオキシ安息香
酸ブチルを入れて溶解した後、希塩酸を用いてＰＨを５
．５に調整する。滅菌精製水を加えて金髪を１０００−
とする。Prescription 210〇-Medium Cromolycate Sodium 2 No ε-7 Minocaproic Acid 0.42 Benzalkonium Chloride
0.005p Chlorobutanol Sodium Chloride Dilute Hydrochloric Acid Sterilized Purified Water Formulation 3 Sodium Cromolycate in 100m C-Aminocaproic Acid Benzalkonium Chlorobutanol Dilute Hydrochloric Acid Sterilized Purified Water Formulation 4 Sodium Cromolycate in 100Wd Sodium Acetate Benzalkonium Chlorobutanol Dilute Hydrochloric Acid Sterilization Purified water prescription 5 1001I/medium cromoglycate sodium 0.25? 0.5y appropriate amount appropriate amount y 0.4y o, o o sy O63y appropriate amount appropriate amount y 0.3 y O,005? 63y Appropriate amount Appropriate amount y 8-Aminocaproic acid 0.4y Benzalkonium chloride o, o o sy Chlorobutanol
0.2y diluted hydrochloric acid Appropriate amount Sterile purified water Appropriate amount Example 2 Prescription 610〇-Medium cromolycate sodium 2yC-aminocaproic acid 0.2y benzalkonium chloride
0.005y Chlorobutanol 0.1! M
'Ethyl paraoxybenzoate o, oo4y Butyl paraoxybenzoate 0.002y Dilute hydrochloric acid
Appropriate amount of sterile purified water Appropriate amount of sterile purified water, sodium cromoglycolate, C-
After adding and dissolving Amitsukagulonic acid, benzalkonium chloride, chlorobutanol, ethyl paraoxybenzoate, and butyl paraoxybenzoate, adjust the pH to 5 using dilute hydrochloric acid.
．． Adjust to 5. Add sterile purified water to make blonde hair 1000-
shall be.
防腐効果試験
ｔｊ塩化ベンザルコニウムとクロロブタノールの併用効
果を調べるために、６関の方法（防菌防黴１２．２９３
（１９８４））を用いて防腐効果試験を行なった。Antiseptic effect test tj In order to investigate the combined effect of benzalkonium chloride and chlorobutanol, the method of 6 Seki (Anti-bacterial and anti-mildew 12.293) was used.
(1984)) was used to conduct a preservative effect test.
本発明の代表例として処方１と処方６のものを用い、比
較対照として表１に示したものを用いた。Formulation 1 and Formulation 6 were used as representative examples of the present invention, and those shown in Table 1 were used as a comparison control.
尚、添加する菌の種類としては、クロモグリク酸ナトＩ
Ｊウムの外用液剤の防腐効果で最も問題があるものがＰ
ｓｅｕｄｏｍｏｎｕｓ ａｅｒｕｇｉｎｏｓａとＣａｎ
ｄｉｄａ ａｌｂｉｃａｎｓ であることから、この
２種の菌を用いて防腐効果試験を行なった。In addition, the types of bacteria to be added include cromoglycate nat I.
The most problematic preservative effect of Jum's external liquid is P.
seudomonus aeruginosa and Can
Since it is a D. albicans species, a preservative effect test was conducted using these two types of bacteria.
以下余白
添加した菌数に対する２週間後の菌の減少率を表に示し
た。The table below shows the reduction rate of bacteria after 2 weeks with respect to the number of bacteria added in the margin.
表２
２週間後の苗減少率
「発明の効果」
表２に示すように、
塩化ベンザルコニウムやパ
ラオキシ安息香酸エステルのみの比較例工と比較例２で
は、菌が完全には死滅していない。又、塩化ベンザルコ
ニウムとパンオキシ安息香酸エステルを併用した比較例
３では防腐効果の増大は認められているもののまだ完全
に菌は死滅していない。Table 2 Seedling reduction rate after 2 weeks ``Effect of the invention'' As shown in Table 2, bacteria were not completely killed in Comparative Example and Comparative Example 2 using only benzalkonium chloride and paraoxybenzoic acid ester. . Furthermore, in Comparative Example 3 in which benzalkonium chloride and panoxybenzoic acid ester were used in combination, an increase in the antiseptic effect was observed, but the bacteria were not completely killed yet.
一方、クロロブタノールを配合した処方１と処方６では
菌が完全に死滅しており、塩化ベンザルコニウムとクロ
ロブタノールの併用効果が明らかとなった。又、処方６
０例で明らかなように塩化ベンザルコニウムとクロロブ
タノールにさらにパラオキン安息４ｉ酸エステルを加え
ることによ抄クロロブタノールの配合量を少なくするこ
ともでき池田願人 参天製薬株式会社On the other hand, in formulations 1 and 6 containing chlorobutanol, bacteria were completely killed, demonstrating the combined effect of benzalkonium chloride and chlorobutanol. Also, prescription 6
As is clear from Example 0, the amount of extracted chlorobutanol can be reduced by further adding paraoxin benzoate to benzalkonium chloride and chlorobutanol. Ganto Ikeda Santen Pharmaceutical Co., Ltd.
Claims (2)
することを特徴とするクロモグリク酸ナトリウムの外用
液剤。(1) An external liquid preparation of sodium cromoglycolate, which is characterized by containing benzalkonium chloride and chlorobutanol.
パラオキシ安息香酸エステルを配合することを特徴とす
るクロモグリク酸ナトリウムの外用液剤。(2) A liquid preparation for external use of sodium cromoglycolate, characterized in that it contains benzalkonium chloride, chlorobutanol, and paraoxybenzoic acid ester.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63277092A JPH02121920A (en) | 1988-10-31 | 1988-10-31 | Solution of sodium cromoglicate for external use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63277092A JPH02121920A (en) | 1988-10-31 | 1988-10-31 | Solution of sodium cromoglicate for external use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02121920A true JPH02121920A (en) | 1990-05-09 |
Family
ID=17578663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63277092A Pending JPH02121920A (en) | 1988-10-31 | 1988-10-31 | Solution of sodium cromoglicate for external use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02121920A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0789857A (en) * | 1993-07-30 | 1995-04-04 | Senju Pharmaceut Co Ltd | Aqueous supension solution |
| JP2001114700A (en) * | 1999-10-14 | 2001-04-24 | Hisamitsu Pharmaceut Co Inc | Eye drop composition |
| JP2006348018A (en) * | 2005-05-16 | 2006-12-28 | Sanwa Kagaku Kenkyusho Co Ltd | Preservative for burkholderia cepacia |
-
1988
- 1988-10-31 JP JP63277092A patent/JPH02121920A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0789857A (en) * | 1993-07-30 | 1995-04-04 | Senju Pharmaceut Co Ltd | Aqueous supension solution |
| JP2001114700A (en) * | 1999-10-14 | 2001-04-24 | Hisamitsu Pharmaceut Co Inc | Eye drop composition |
| JP2006348018A (en) * | 2005-05-16 | 2006-12-28 | Sanwa Kagaku Kenkyusho Co Ltd | Preservative for burkholderia cepacia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3612228B1 (en) | Iodine compositions | |
| BRPI9906735B1 (en) | 'aqueous liquid pharmaceutical composition and method for preventing crystal precipitation and for preventing gatifloxacin staining.' | |
| JP7417365B2 (en) | aqueous ophthalmic composition | |
| JPH1160505A (en) | Antiseptic composition | |
| JPH02264716A (en) | Tranilast aqueous solution preparation | |
| ES2393675T3 (en) | Preservative composition for ophthalmic use | |
| JPH085800B2 (en) | Aqueous formulation containing lysozyme chloride and dipotassium glycyrrhizinate | |
| JPH08291065A (en) | Pranoprofen eye drop containing organic amine blended therein | |
| KR19980033113A (en) | Aqueous solutions of local anesthetics, how to improve the solubility of local anesthetics, local anesthetics with reduced neurotoxicity and methods of reducing the neurotoxicity of local anesthetics | |
| JP4355574B2 (en) | Eye drops | |
| JPS62190121A (en) | Water-based liquid agent | |
| JPS63174930A (en) | Aqueous composition of quinolonecarboxylic acid | |
| US5276044A (en) | Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions | |
| JPH02121920A (en) | Solution of sodium cromoglicate for external use | |
| JP3502574B2 (en) | Eye ointment for treatment of eye infections | |
| JP5013735B2 (en) | Ocular mucosa application | |
| JP4801300B2 (en) | Liquid composition for external use | |
| JPH075456B2 (en) | Eye drops | |
| JP2001048780A (en) | Stabilization of aqueous solution of vitamins and stable liquid vitamin preparation | |
| JPH0717863A (en) | Pranoprofen ophthalmic preparation | |
| JPH0674212B2 (en) | Method for preventing contraindications for aqueous formulations containing benzalkonium chloride | |
| JPH02193931A (en) | Eye drop for treating keratopathy | |
| JP4813682B2 (en) | Ophthalmic agent | |
| JP4132461B2 (en) | Ophthalmic liquid composition | |
| SA90110074B1 (en) | Pharmaceutical compositions containing an aqueous solution of a pyranoquinoline derivative |